Clinical Trial

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-10; most recent amendment 2026-07-13.
Status change: Not Yet Recruiting → Recruiting 2026-04-24
Trial Details
NCT Number NCT07286032
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Patients With Chemotherapy-Induced Thrombocytopenia
Enrollment 150 participants
Start Date 2026-04-16
Primary Completion 2028-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-14